Objectives: Adverse events (AEs) of ischemic colitis (IC) and complications of constipation (CoC) associated with alosetron are rare and have been adjudicated during the first 5.5 years of the risk management program (RMP); however, changes in incidence rates relative to reductions in AE reports and increases in alosetron prescriptions over the 9-year RMP have not been evaluated. The authors aim to evaluate temporal trends in alosetron postmarketing safety over the 9-year RMP. Methods: The alosetron safety database was searched to identify cases of IC, CoC, and related AEs from 20 November 2002 to 31 December 2011. Adjudication of IC and CoC cases were based on US Food and Drug Administration-defined criteria. Incidence rates were calculated using the number of AEs and alosetron prescriptions (expressed as cases/1000 patient-years exposure). Results: A total of 29 cases were adjudicated as probable/possible IC and 7 cases were adjudicated as CoC. Cumulative adjudicated incidence rate of IC (1.03 cases/1000 patientyears) is low and stable, while that of CoC (0.25 cases/1000 patient-years) is low, declining progressively over time. Decreases in the incidence rates of potential symptoms of IC (abdominal pain with bloody diarrhea/hematochezia) and CoC (constipation) were also observed. Conclusions: Over the 9-year RMP period, incidence rates of IC and CoC remain rare. Substantial reductions over time were observed in the incidence of CoC and in symptoms suggestive of IC or CoC, while IC incidence has been stable at approximately 1.0 case/1000 patient-years. Decreases in AEs and serious outcomes associated with IC and CoC since the reintroduction of alosetron are likely attributable to the RMP.
Introduction
Alosetron is a selective 5-HT 3 receptor antagonist currently approved for the treatment of women with severe diarrhea-predominant irritable bowel syndrome (IBS-D), who have had an inadequate response to conventional therapy [Prometheus Laboratories Inc., 2010] . Results from clinical studies have demonstrated significant efficacy for alosetron in IBS, particularly in improving fecal urgency, stool frequency, and consistency [Camilleri et al. 2000 [Camilleri et al. , 2001 . Moreover, in female patients with severe IBS-D, alosetron has been shown to improve global symptoms of IBS and provide adequate relief of IBS pain and discomfort [Lembo et al. 2004; Krause et al. 2007; Chey et al. 2004] . Based on the collective evidence on its efficacy in clinical trials, alosetron was initially approved in the USA in February 2000.
Reported adverse events (AEs) that occurred at a greater frequency in IBS patients receiving alosetron 1 mg twice daily than in placebo-treated patients included constipation, abdominal pain and discomfort, and nausea. In these clinical trials, alosetron was associated with infrequent but serious gastrointestinal AEs of ischemic colitis (IC) and complications of constipation (CoC). The cumulative incidence of IC in female patients with IBS treated with alosetron was 0.2% through 3 months and 0.3% through 6 months [Prometheus Laboratories Inc., 2010] . Overall, a statistically significant increase in the incidence of IC was observed from clinical trials in alosetrontreated patients compared with placebo (0.15% versus 0.00%, p = 0.03); however, no significant differences were seen with CoC [Chang et al. 2006 ]. Due to postmarketing reports of IC and CoC following its approval, alosetron was voluntarily withdrawn by GlaxoSmithKline only 9 months later. In November 2002, in response to requests from individuals with IBS and patient advocacy groups, the US Food and Drug Administration (FDA) and GlaxoSmithKline reached an agreement to reintroduce alosetron to the US market under a risk management program (RMP) [FDA, 2002] .
The alosetron RMP was created based on the FDA's risk minimization action plan (RiskMAP) with the goal of mitigating serious outcomes of IC and CoC [FDA, 2005] . The various elements of the alosetron RMP were intended to educate physicians and patients on the risks and benefits of treatment, signs and symptoms of IC and CoC, and appropriate management of these AEs, if they occur. The RMP consisted of the prescribing program for Lotronex ™ , a medication guide, and patient follow-up survey. Also, the alosetron indication was restricted to female patients with chronic, severe IBS-D, and recommended that patients meet at least one of three severity criteria: (a) frequent and severe abdominal pain/discomfort; (b) frequent bowel urgency or fecal incontinence; and/or (c) disability or restriction of daily activities due to IBS symptoms [Miller et al. 2006 ]. The RMP has since been converted to a risk evaluation and mitigation strategy (REMS) program in September 2010 [FDA, 2013] . Hereafter in this report, the term RMP is used globally to refer to either FDA-mandated RiskMAP (November 2002 -August 2010 ), or REMS (September 2010 program for risk management.
An analysis of postmarketing safety data with alosetron under the RMP was previously performed by Chang and colleagues, who evaluated the incidence, clinical characteristics, and outcomes of IC and CoC from November 2002 to June 2008 [Chang et al. 2010] . During this period, a total of 29,072 patients received 203,939 prescriptions of alosetron. Following FDA-defined adjudication criteria, the incidence of probable/ possible cases of IC and CoC were found to be rare in occurrence, as supported by incidence rates of 0.95 cases/1000 patient-years for IC and 0.36 cases per 1000 patient-years for CoC. These incidence rates were similar to those observed for IC and CoC during the initial postmarketing surveillance period up to February 2004 [Chang et al. 2006] . No surgeries or deaths were observed in patients with probable/possible IC and CoC. Chang and colleagues demonstrated that the RMP was effective in mitigating serious outcomes of IC and CoC associated with alosetron during the initial 5.5 years since its implementation [Chang et al. 2010] .
Following the reintroduction of alosetron under the RMP in November 2002, alosetron prescriptions were initially low but have increased over time. An estimated 340,000 prescriptions corresponding to approximately 28,000 patient-years of drug exposure have been recorded under the RMP. Therefore, the aims of this report are: (a) to provide a 9-year analysis of the incidence and characteristics of IC and CoC cases in the postmarketing population of patients with severe IBS-D treated with alosetron under the RMP; (b) to evaluate temporal trends (i.e. changes over time) in the incidence rates of probable/possible IC, CoC, and other clinically relevant AEs over the 9-year period of the RMP; (c) to assess the effectiveness of the alosetron RMP in mitigating clinically relevant AEs (i.e. abdominal pain accompanied by hematochezia or bloody diarrhea and constipation), and serious outcomes associated with IC and CoC (e.g. death, surgery, transfusion, hospitalization); (d) to explore clinical characteristics and presentation associated with IC and CoC.
Materials and methods
The methodology for this analysis has been previously described in detail by Chang and colleagues [Chang et al. 2010] . A summary of this methodology, including any differences with the present analysis, is provided below.
Data sources
The alosetron safety database, which contained only postmarketing AE reports for patients who received alosetron under the RMP, was used to identify potential cases of IC and CoC. AEs of IC and CoC from clinical trials were not included in this analysis. Potential cases for the current analysis were extracted during the period from 20 November 2002 to 31 December 2011. Demographic data for patients including age, presenting symptoms, concomitant medications, concurrent medical conditions, and AE-related information (i.e. time to onset, duration of illness, hospitalization, and outcomes) were obtained from FDA MedWatch forms.
Selection, screening, and adjudication of potential cases of IC and CoC
The following keywords from the Medical Dictionary for Regulatory Activities (MedDRA), version 10.1, were used to search the alosetron safety database to identify all potential cases of IC: colitis ischemic, intestinal ischemia, and colitis as a serious AE. A search for MedDRA terms that may have described symptoms of potential IC cases was also performed, including abdominal pain, abdominal discomfort, gastrointestinal pain, gastrointestinal discomfort, hematochezia, bloody diarrhea, and diarrhea hemorrhagic. Potential IC cases were adjudicated to determine if there was substantial evidence to support an IC diagnosis and were deemed either probable, possible, or unlikely IC according to the criteria established during discussions between the FDA and the sponsor in 2002 [FDA, 2002] .
MedDRA terms determined by the FDA and the sponsor to be potential diagnoses for CoC were obstruction, perforation, intestinal ulceration, toxic megacolon, ileus, and impaction resulting in hospital admissions (i.e. fecal impaction as a serious AE) [FDA, 2002] . To account for the difference in AE-coding conventions used by the former sponsor, MedDRA search terms for the present analysis included colonic stenosis, gastrointestinal pain, ileal perforation, ileus, ileus paralytic, intestinal obstruction, intestinal perforation, impaired gastric emptying, large intestinal perforation, lower gastrointestinal hemorrhage, small intestinal obstruction, and serious AEs of bowel obstruction, megacolon, fecal impaction, and fecal perforation. Criteria for CoC included medical history, reported diagnoses, and supportive test results that were consistent with one of the above listed diagnoses of CoC.
Two gastroenterologists (LC and EC) independently reviewed and evaluated all potential cases of IC or CoC identified from the alosetron safety database. One of the reviewers (LC) was involved in previous adjudications of the safety data [Chang et al. 2006 [Chang et al. , 2010 .
Data analyses
The annual and total number of alosetron prescriptions and patients receiving prescriptions were monitored under the RMP. Each prescription was considered to represent 1 month of alosetron use to determine the extent of exposure in the postmarketing population. Incidence rates were calculated (cases per 1000 patient-years of exposure) for IC and CoC for the period prior to withdrawal and the period after reintroduction of alosetron to the US market. The reported incidence rate includes all potential IC and CoC cases (pre-adjudication) identified from the alosetron safety database using the search strategy described above. The adjudicated incidence rate includes all reported cases of IC and CoC that were determined to be probable or possible for the diagnoses of IC and CoC. Cumulative incidence rates for IC, CoC, and other clinically relevant AEs were calculated for each year beginning with 2003 (which included approximately 6 weeks of data from 2002: 20 November-31 December) through to the end of 2011 using reported and adjudicated cases. Cumulative incidence rate was calculated by the accumulated IC or CoC cases divided by the number of cumulative prescriptions during the 9-year period.
Postmarketing AE reports of abdominal pain and hematochezia or bloody diarrhea were queried from the safety database over the 9-year period after reintroduction to evaluate the reported incidence rate for potential symptoms indicative of IC. Similarly, AEs of constipation were queried during this period to evaluate the reported incidence rate of potential symptoms indicative of CoC. Additional clinical data (i.e. age, time to onset, duration of symptoms, alosetron dosage, comorbidities, concomitant medications, and outcomes) available from probable/possible IC and CoC cases were extracted from the FDA MedWatch Forms. The characteristics, demographics, clinical symptoms, and outcomes for all probable or possible cases of IC and CoC were summarized overall and by time period (before alosetron withdrawal and after reintroduction under RMP). In addition, characteristics of the probable/possible IC cases were examined for the following subgroups to investigate clinically meaningful trends: age group (≤ 50 years, > 50 years); time to onset of IC (≤ 120 days, earlyonset; > 120 days, late-onset); duration of IC symptoms (≤ 5 days, short; > 5 days, long), and hospitalization status (hospitalized, not hospitalized). Since this study was based on postmarketing case reports and not designed to test any statistical hypothesis, only descriptive statistics (e.g. means, counts and percentages) of the data are presented and summarized.
Results
During the 9-year postmarketing period under the RMP, a total of approximately 32,000 patients used 341,784 prescriptions of alosetron, corresponding to an estimated 28,084 patient-years of alosetron exposure. In total, 43 potential cases of IC and 26 potential cases of CoC were identified for further analysis and adjudication. Of these, 29 probable or possible cases of IC and 7 cases of CoC were identified, which correspond to adjudicated incidence rates of 1.03 cases/1000 patient-years and 0.25 cases/1000 patient-years, respectively. The overall incidence rates for IC and CoC associated with alosetron over the 9-year period of the RMP are compared with the rates observed for the period prior to reintroduction in Table 1 .
IC cases
The 29 cases of probable/possible IC all occurred in women with a median age of 55 years taking a median total daily dose of alosetron 1 mg. Median time to onset of IC symptoms was 114 days with a median duration of 6 days. With respect to the clinical presentation of probable/possible IC cases, the most common symptoms were abdominal pain (90%) followed by hematochezia or bloody diarrhea (83%), and nausea/vomiting (38%), with abdominal pain accompanied by hematochezia reported in 72% of cases. Constipation at presentation was observed in 21% of IC cases. All probable/possible cases of IC were confirmed by healthcare providers, with biopsy findings consistent with IC obtained in 76% of cases. Additional details regarding demographics, clinical characteristics, and outcomes of these probable/possible IC cases are summarized in Table 2 .
Information regarding the age of alosetron patients who developed IC was available for 28 patients. Of these 28 patients, those who had experienced probable/possible IC tended to be older, with 68% (n = 19) of cases occurring in patients over 50 years of age. Furthermore, patients over 50 years of age, compared with their younger counterparts, experienced: (a) a longer (delayed) time to onset of IC after initiating alosetron therapy (224 days versus 52 days); (b) a higher prevalence of comorbid illnesses (53% versus 44%); (c) a greater likelihood of hospitalization for treatment of IC (63% versus 22%). Median duration of illness and average total daily dose of alosetron (1 mg) were similar in older and younger patients. IC. Early-onset IC patients were more likely to have comorbidities than those with late-onset IC (71% versus 15%). Hospitalizations occurred twice as often in the early-onset patients than in those with late-onset IC (57% and 31%, respectively).
Data on duration of IC symptoms were available for 21 patients and divided into categories of 5 days or fewer (short duration, n = 10), and greater than 5 days (long duration, n = 11). Median duration of IC symptoms was 3 days and 14 days for patients with short versus long duration of symptoms, respectively. All 10 patients (100%) with a short duration of IC had comorbid illnesses or took concomitant medications that may have predisposed them to IC, compared with 64% of patients with long duration. Patients with a short duration were hospitalized for treatment in 80% of cases, compared with a hospitalization rate of 27% for those with IC of long duration. Median age, median time to onset of symptoms, and mean alosetron dose were similar in patients with short versus long duration of IC, respectively: age, 59 years versus 58 years; time to onset, 49 days versus 52 days; average daily dose, 1 mg for both groups.
Three patients (10%) had emergency room visits and 14 patients (48%) were hospitalized related to IC. The median duration of hospitalization was 3 days, ranging from 1 to 14 days. All but three of the hospitalized patients had hospital stays of 3 days or less. Patients who were hospitalized tended to be older (61 years versus 49 years for patients who were not hospitalized), on concomitant medications or have comorbidities (93% versus 67%), and have a shorter time to onset of IC symptoms (36 days versus 510 days). Median total daily dose of alosetron was similar for hospitalized and nonhospitalized patients (0.9 mg versus 1.1 mg).
Of the 14 IC cases that required hospitalization, 1 patient with several comorbidities and concomitant medications required surgery. The patient was a 60-year-old female with a medical history of IBS-D, which was initially diagnosed 4 years prior to the IC event; other comorbidities were atherosclerotic vascular disease, hyperlipidemia, hypertension, diabetes mellitus, hepatomegaly, kidney disease, peritoneal adhesions, hemorrhoids, obesity, anemia, and arthritis. Approximately 1 month prior to hospitalization, she saw her gastroenterologist complaining of worsening diarrhea, lower abdominal cramping, pain, and urgency, and was subsequently prescribed alosetron 0.5 mg once daily. A few days after initiating therapy, she reported experiencing constipation and was instructed to discontinue alosetron for 3 days and restart at a lower dose. Approximately 2 weeks later, she began experiencing intermittent diarrhea and constipation accompanied by severe abdominal pain and was hospitalized. At the time of hospitalization, the patient's concomitant medications included simvastatin, triamterene/ hydrochlorothiazide, metronidazole, propoxyphene, nabumetone, belladonna/phenobarbital, and hyoscyamine. A surgical procedure was performed and involved an exploratory laparotomy, lysis of adhesions, sigmoidectomy with Hartmann's procedure, and appendectomy with decompression of the colon. Pathological findings were consistent with IC. The patient recovered shortly thereafter and was discharged from the hospital 14 days after admission.
Among the 29 IC cases, there were no deaths, transfusions, or occurrences of mesenteric ischemia reported. Bowel surgery was performed in one case of probable/possible IC, as described. All 29 IC cases either resolved or improved. In general, IC events in the postmarketing period under the RMP were transient, self-limited, and resolved without sequelae (Table 3) .
CoC cases
A total of seven cases, adjudicated as CoC, were found from the alosetron postmarketing safety database. A summary of the demographics, clinical characteristics, and outcomes of these CoC cases is presented in Table 4 . These seven confirmed cases of CoC were due to bowel obstruction (four cases), fecal impaction (two cases), and ileus (one case); five cases occurred in women and two in men. Notably, only one case of CoC has been reported since 2008. The median age of patients with CoC was 45 years. Median time to onset of CoC symptoms was 23 days, median duration of CoC events was 2 days, and median total daily dose of alosetron was 2 mg. Two patients (29%) had comorbidities at the onset of CoC, including hypothyroidism and hypokalemia in one patient and diabetes in the other. The first patient's hypothyroidism was being treated with levothyroxine; the second patient with diabetes was taking metformin and sitagliptin. Overall, concomitant medication use was common and included antidepressants or psychotropics (57%, n = 4), antidiarrheals (43%, n = 3), and narcotic analgesics (14%, n = 1). A majority of CoC cases (57%, n = 4) occurred within the first 30 days of alosetron treatment. Two patients (29%) had previously been treated with alosetron during the initial marketing period in 2000 without experiencing clinically significant AEs. Five (71%) of the CoC cases resulted in hospitalization. All CoC cases for which follow-up information was available (six cases) were confirmed to have resolved. One case was lost to follow up (outcome unknown). No deaths, perforation of the intestine, toxic megacolon, or surgeries were reported in patients with CoC over the 9-year period of the RMP (Table 5) .
Temporal trends in incidence rates of IC and CoC
The adjudicated incidence rates of probable/ possible IC in alosetron users remained at low levels in the periods before and after the implementation of the RMP (0.96 cases/1000 patientyears versus 1.03 cases/1000 patient-years, respectively [ Table 1 ]). Over the 9-year period of the RMP, the cumulative adjudicated incidence rate of probable/possible IC has continually been low and stable at approximately 1.0 case/1000 patient-years (Figure 1 ). Analysis of AE reports from the alosetron safety database of abdominal pain accompanied by hematochezia/ bloody diarrhea, symptoms that may strongly indicate a case of IC, shows a decline in these AEs under the RMP (Figure 2) . The reported incidence rate of abdominal pain with hematochezia/bloody diarrhea decreased seven-fold from 2003 to 2011.
In contrast to IC, the adjudicated incidence rate of CoC in alosetron patients has declined considerably under the RMP compared with the rate prior to reintroduction. The adjudicated incidence rate of CoC cases prior to reintroduction was 0.59 cases/1000 patient-years, compared with a rate of 0.25 cases/1000 patient-years after reintroduction under the RMP (Table 1) . Of the seven cases of CoC since reintroduction, six occurred from 2002 through 2007, with one case reported from 2008 through 2011. During the 9-year period of the RMP, the cumulative adjudicated incidence rate of CoC has been low, and has progressively declined over time (Figure 3 ). This reduction in the adjudicated incidence rate of CoC has been paralleled by a marked decrease (8.5-fold) in reports of AEs of constipation under the RMP (Figure 2 ). 
Discussion
The current study demonstrates the stable and decreasing incidence rates over time of adjudicated cases of IC and CoC, respectively, associated with alosetron since implementation of the RMP. Since the previous study [Chang et al. 2010] , this analysis contributes an additional 3.5 years of postmarketing safety data, which corresponds to approximately 11,300 patient-years, and amounts to an overall total of 28,084 patient-years of exposure to alosetron therapy. These data are important as there are limited published data on the postmarketing safety and corresponding clinical outcomes associated with therapeutic agents, particularly those under a RMP, over a relatively long period of time.
Temporal trends over the 9 years of the alosetron RMP demonstrate that incidence rates of probable/possible IC and CoC remain rare. The adjudicated incidence rate of IC has been stable at approximately 1.0 cases/1000 patient-years, which is similar to the inherent background rate of IC in IBS patients that ranges from 0.40 cases/1000 patient-years to 1.79 cases/1000 patient-years [Cole et al. 2004; Walker et al. 2004 ; et al. 2004] . Epidemiological studies have consistently demonstrated that IBS itself is an independent risk factor for IC, and have shown that patients with IBS have a two-to four-fold greater risk of developing IC than those without IBS Hervé et al. 2009; Chang et al. 2008] . Given the apparent increased background rate of IC among patients with IBS, the of the idiopathic nature of IC due to multiple pathophysiologic factors (e.g. age, comorbidities, concomitant medications, surgical history, etc.) that potentially contribute to its development [Chang et al. 2008; Brandt and Boley, 2000; Hass et al. 2007 ]. Considering the epidemiological evidence to date with IC, IBS, and alosetron, another possibility is that the incidence rate of IC with alosetron is reflective of the background rate of IC in IBS patients. However, more rigorous casecontrol studies in IBS patients would be required to investigate this hypothesis.
Singh
Exploratory analyses of patient demographics and medical histories during the 9-year period since reintroduction suggest potential risk factors for the development of IC. Age appears to be a factor in the occurrence of IC in alosetron users, with 68% of cases occurring in patients older than 50 years. The median age of alosetron patients with probable/possible IC was 55 years, both prior to reintroduction and postreintroduction to the US market. Moreover, approximately half of patients with IC were taking concomitant medication (52%), or had concurrent medical conditions (48%) with possible links to IC [Cole et al. 2004; Zervoudis et al. 2008; Deana and Dean, 1995; Preventza et al. 2001; Charles et al. 2005; Schwartz and Smith, 2004; Knudsen et al. 1998; Radaelli et al. 2005; Thiéfin and Beaugerie, 2005; Gandhi et al. 1996; Matsumoto et al. 1994 ]. These factors were also higher in patients with IC who were hospitalized compared with those who were not. These findings are consistent with previous reports on IC and have been observed in patients treated with alosetron, as well as in the general IBS population, which implies that these risk factors are likely nonspecific [Chang et al. 2006 [Chang et al. , 2008 [Chang et al. , 2010 Cole et al. 2004; Walker et al. 2004; Hervé et al. 2009; Brandt and Boley, 2000; Hass et al. 2007; Sotiriadis et al. 2007; Longstreth and Yao, 2009; Lewis, 2010; Suh et al. 2007] . The relationship between alosetron use in IBS patients, concomitant medications or comorbidities, and incidence of IC, however, remains unclear and warrants further elucidation.
Most cases of IC observed after the implementation of the RMP were self-limited and all resolved or improved after discontinuation of alosetron. An overall decrease of 19% in the number of probable/possible IC cases that required hospitalization was seen since reintroduction under the RMP (48% versus 67% prior to reintroduction).
In addition, there has been a lower percentage of cases requiring intestinal surgery (1.7% versus 5.2%), no cases requiring transfusions (0% versus 1.7%), and a greater proportion of cases that resolved or improved (100% versus 77.5%). There was only one IC case that required intestinal surgery since the RMP was introduced. The patient had several risk factors for IC including older age, multiple comorbidities, and use of several concomitant medications.
In contrast to the relatively stable incidence of IC, the incidence rate of adjudicated CoC cases in the postmarketing alosetron population has decreased by 58% since the RMP was implemented. 1998; Locke et al. 2000; Shafer et al. 1984; Sartoretti et al. 1996; Vinik et al. 2003 ]. The use of lower doses of alosetron and cautious evaluation of any potential AEs related to constipation likely has decreased incidences of both constipation and CoC.
Importantly, while annual prescribing of alosetron under the RMP increased 35% from 2003 (31,645 prescriptions) to 2011 (42,701 prescriptions) (from Source® Prescriber database), adjudicated incidence rates of IC and CoC have remained rare, and reported incidence rates of clinically related AEs (i.e. abdominal pain with hematochezia/bloody diarrhea and constipation) have declined 7-to 8.5-fold. These data strongly suggest that increased prescriber and patient education on the signs and symptoms of IC, CoC, and constipation resulting in early recognition and clinical management of potentially serious AEs, as intended by the RMP, may be a reason for these observed decreases in adjudicated and reported incidence rates. Furthermore, this analysis demonstrates that the vast majority of reported cases of abdominal pain with hematochezia/bloody diarrhea or constipation was not due to confirmed cases of IC or CoC, as evidenced by the large discrepancies between adjudicated IC or CoC cases and reported presenting symptoms.
Certain limitations and strengths are associated with the use of postmarketing AE data. General limitations include the potential for underreporting of AE data owing to the fact that AE reporting is voluntary for healthcare professionals, the lack of certainty in determining whether an AE is caused by the drug or due to the underlying disease and/or concomitant medications, the high variability in the amount and quality of information contained in postmarketing AE reports, and the inability to estimate accurately the denominator for incidencerate calculations [Goldman, 1998; Fletcher, 1991; Begaud et al. 1994] . In this study, alosetron exposure was calculated from prescription data based on the assumption that all prescriptions represented 1 month of alosetron use, when in fact, the specific duration of alosetron use for each patient was unknown. Additionally, bias and fluctuations in AE-reporting rates over time may be attributed to educational activities and/or regulatory actions (e.g. medical education lectures and publications, and FDA-mandated AE notifications), which raise awareness and can increase reporting rates [Weiss-Smith et al. 2011; Weber, 1984] .
The strengths of postmarketing AE data include the possibility for early detection of potential safety signals, identification of rare AEs not previously identified in controlled conditions such as clinical trials, and the ability to evaluate realworld use and clinical outcomes [Goldman, 1998; Fletcher, 1991] . Furthermore, under the alosetron RMP, serious AEs are required to be reported by the enrolled physicians, and pharmaceutical manufacturers of FDA-approved drugs and biologics are required by law to monitor and report AEs [FDA, 2012] .
It is likely that the increased awareness, and prompt recognition and treatment of these AEs resulting from physician training and patient education as intended by the RMP have contributed to mitigating the serious outcomes of IC and CoC associated with the use of alosetron. The possibility that the RMP is enabling prescribers to better identify appropriate patients for alosetron and facilitate recognition of symptoms associated with IC and CoC is supported by the decline in reported incidence rates of abdominal pain accompanied by hematochezia or bloody diarrhea and constipation, respectively, as seen over the entire 9-year period of the RMP (Figure 2 ). Consistent with these data, results from several analyses of the alosetron patient follow-up survey have also indicated that most patients met or exceeded the clinical criteria for severe IBS-D, were well informed of the risks and benefits of alosetron use, and were highly compliant with the elements of the RMP over time [Miller et al. 2006; Nicandro et al. 2012; Tennis et al. 2007 ]. The additional postmarketing safety data presented in the current study, coupled with previous evidence of the high level of compliance with the various elements of the RMP, suggest that the alosetron RMP is achieving its objective of appropriately balancing the risks and benefits of alosetron therapy.
In summary, the present analysis shows that among alosetron patients treated during the 9 years since reintroduction under the RMP, the overall adjudicated incidence rate of IC cases has remained rare and stable, while the adjudicated incidence rate of CoC cases has sharply decreased compared with the period before withdrawal. Under the alosetron RMP, the number of serious outcomes of IC has decreased, with no transfusions or deaths. A dramatic and progressive decline in the rate of CoC cases has occurred, with no serious outcomes of CoC (including perforations, surgeries, or deaths). Decreases in the reported incidence rates of clinically relevant symptoms potentially indicative of IC (abdominal pain with hematochezia or bloody diarrhea) and CoC (constipation) were also observed. Appropriate patient selection along with a high degree of physician and patient compliance with the various elements of the RMP appear to have resulted in mitigating the AEs and serious outcomes associated with IC and CoC over the 9 years of alosetron use under the RMP.
